Your session is about to expire
← Back to Search
Ibrexafungerp for Histoplasmosis (FURI Trial)
FURI Trial Summary
This trial will test a new drug, ibrexafungerp, for people with a fungal disease who haven't responded to other treatments. The drug's safety and effectiveness will be evaluated.
- Histoplasmosis
- Invasive Candidiasis
- Valley Fever
- Oral Thrush
- Blastomycosis
- Chronic Pulmonary Aspergillosis
- Allergic Bronchopulmonary Aspergillosis
- Invasive Pulmonary Aspergillosis
- Vaginal Yeast Infection
- Emerging Fungal Infections
FURI Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2019 Phase 3 trial • 376 Patients • NCT03734991FURI Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
Can you share any additional information about other Ibrexafungerp research projects?
"Ibrexafungerp is being trialled in 85 locations worldwide, with the majority of these studies taking place in Bangalore, Karnataka. Currently, there are 4 active trials for Ibrexafungerp, 3 of which are Phase 3 trials."
Are there different sites where this clinical trial is taking place?
"This clinical trial is being conducted at Washington University School of Medicine, University of Texas Southwestern Medical Center Dallas, University of Pittsburg Medical Center, and 21 other locations."
Are people still being enrolled in this experiment?
"The trial, which was originally advertised on 2017-04-01, is still recruiting patients, as is evident on clinicaltrials.gov. The study's administrators made their most recent edit on 2022-07-22."
What other similar research projects exist?
"Ibrexafungerp is being studied in 4 ongoing global clinical trials. The first trial occurred in 2017 and, since then, 9 more have completed. The initial study, which led to the drug's Phase 3 approval, was sponsored by Scynexis, Inc. and had 200 participants."
What is the government's stance on Ibrexafungerp?
"Given that this is a Phase 3 trial with available data supporting both efficacy and safety, our team at Power has given Ibrexafungerp a safety rating of 3."
Who else is applying?
What state do they live in?
How old are they?
What site did they apply to?
What portion of applicants met pre-screening criteria?
Share this study with friends
Copy Link
Messenger